Company: NCEL
Filing Date: 2025-06-23
Form Type: F-4/A
Source: 0001213900-25-056787
Chunk: 464

Company: NewcelX Ltd.
Filing Date: 2025-06-23
Form: F-4/A
Chunk 464
---
 of the transaction costs recorded as of December31, 2024 of $743,838. For the transactions costs incurred and recorded subsequent to December31, 2024, $250,000 has been paid in cash and $300,000 has been accrued for purposes of payment subsequent to the closing; (E)Adjustment to record additional non -recurringKadimastem transaction costs of approximately $300,000 for legal, audit and other professional service provider expenses that were not incurred or accrued as part of the transaction costs recorded as of December31, 2024 of $268,729. For the transactions costs incurred and recorded subsequent to December31, 2024, $100,000 has been paid in cash and $200,000 has been accrued for purposes of payment subsequent to the closing; 269 (F)Adjustment for $16,246 to record conversion of 491,532 of the Company’s preferred participation certificates, par value CHF 0.03 per certificate (“PPCs”), pursuant to the securities purchase agreement entered into a with an accredited investor on October9, 2024 to satisfy $4.0million of our debt (“October Debt SPA”) into 700,000 NLS Common Shares issued which included anti -dilutionshares as outlined per the agreement and resulted in adjustment of $23,136; (G)Adjustment of $1,983 to record 60,000 PPCs, par value CHF 0.03 per certificate, convertible into NLS Common Shares issued in addition to anti -dilutionNLS Common Shares referenced above in satisfaction of the anti -dilutionrights of the Selling Shareholder under the October Debt SPA; (H)To record $14,799 in connection with a NLS Common Shares purchase agreement with Alpha Capital Anstalt (“Alpha”), dated March31, 2025, whereby the Company agreed to issue Alpha 435,000 NLS Preferred Shares to compensate the investor for certain price protection issuances and registration obligations; (I)Adjustment for the twelve months ended December31, 2024 of $61,438 to accelerate share -basedcompensation expense for NLS options based on IFRS accounting requirements at closing of merger; (J)Adjustment for gross cash proceeds of approximately $2,207,555 related to Kadimastem convertible loans and associated warrants converted and exercised at the time of Closing. The loan agreements entered on October16, 2023, from several shareholders include warrants